Zafgen Company Profile (NASDAQ:ZFGN)

About Zafgen (NASDAQ:ZFGN)

Zafgen logoZafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZFGN
  • CUSIP: N/A
  • Web:
  • Market Cap: $111.4 million
  • Outstanding Shares: 27,372,000
Average Prices:
  • 50 Day Moving Avg: $4.71
  • 200 Day Moving Avg: $4.07
  • 52 Week Range: $2.89 - $7.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.14
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.05 per share
  • Price / Book: 1.00
  • EBIDTA: ($52,030,000.00)
  • Return on Equity: -47.40%
  • Return on Assets: -43.01%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 12.49%
  • Quick Ratio: 12.50%
  • Average Volume: 205,681 shs.
  • Beta: -1.24
  • Short Ratio: 3.62

Frequently Asked Questions for Zafgen (NASDAQ:ZFGN)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.05. View Zafgen's Earnings History.

Where is Zafgen's stock going? Where will Zafgen's stock price be in 2017?

4 brokerages have issued 12 month target prices for Zafgen's stock. Their forecasts range from $4.00 to $60.00. On average, they expect Zafgen's share price to reach $16.80 in the next year. View Analyst Ratings for Zafgen.

What are analysts saying about Zafgen stock?

Here are some recent quotes from research analysts about Zafgen stock:

  • 1. According to Zacks Investment Research, "Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. " (5/13/2017)
  • 2. Cowen and Company analysts commented, "Zafgen reported a Q4:16 net loss of $10.4MM, ended 2016 with $129.2MM in cash,." (3/10/2017)

Who are some of Zafgen's key competitors?

Who owns Zafgen stock?

Zafgen's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (14.88%), Vanguard Group Inc. (2.79%), JPMorgan Chase & Co. (1.81%), Foresite Capital Management II LLC (1.64%), Dimensional Fund Advisors LP (1.62%) and Royce & Associates LP (1.39%). Company insiders that own Zafgen stock include Avi Y Goldberg, Dennis D Kim, Frances K Heller, James E Flynn, Kevin P Starr, Patricia L Allen and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.

Who sold Zafgen stock? Who is selling Zafgen stock?

Zafgen's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, Spark Investment Management LLC, Royce & Associates LP, Foresite Capital Management III LLC, Morgan Stanley and FMR LLC. View Insider Buying and Selling for Zafgen.

Who bought Zafgen stock? Who is buying Zafgen stock?

Zafgen's stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., Vanguard Group Inc., TIAA CREF Investment Management LLC, Wells Fargo & Company MN and Nine Chapters Capital Management LLC. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim, Frances K Heller, James E Flynn, Patricia L Allen and Thomas E Hughes. View Insider Buying and Selling for Zafgen.

How do I buy Zafgen stock?

Shares of Zafgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Zafgen stock cost?

One share of Zafgen stock can currently be purchased for approximately $4.07.

Analyst Ratings

Consensus Ratings for Zafgen (NASDAQ:ZFGN) (?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $16.80 (312.78% upside)

Analysts' Ratings History for Zafgen (NASDAQ:ZFGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$9.00HighView Rating Details
3/10/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
3/7/2017FBR & CoReiterated RatingMarketperformLowView Rating Details
7/21/2016Canaccord GenuitySet Price TargetHold$7.00 -> $4.00N/AView Rating Details
7/20/2016Leerink SwannReiterated RatingMarket Perform$6.00N/AView Rating Details
4/5/2016Royal Bank of CanadaReiterated RatingOutperform$19.00N/AView Rating Details
2/20/2016SunTrust Banks, Inc.Reiterated RatingHold$7.00N/AView Rating Details
10/16/2015JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Zafgen (NASDAQ:ZFGN)
Earnings by Quarter for Zafgen (NASDAQ:ZFGN)
Earnings History by Quarter for Zafgen (NASDAQ:ZFGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.43)($0.48)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.50)($0.38)ViewListenView Earnings Details
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Zafgen (NASDAQ:ZFGN)
2017 EPS Consensus Estimate: ($2.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.49)($0.41)($0.45)
Q2 20172($0.58)($0.53)($0.56)
Q3 20172($0.64)($0.58)($0.61)
Q4 20172($0.70)($0.64)($0.67)
(Data provided by Zacks Investment Research)


Dividend History for Zafgen (NASDAQ:ZFGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Zafgen (NASDAQ:ZFGN)
Insider Ownership Percentage: 20.30%
Institutional Ownership Percentage: 50.64%
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)
Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Dennis D. KimInsiderBuy10,000$4.40$44,000.00View SEC Filing  
12/19/2016Frances K HellerDirectorBuy10,000$3.23$32,300.00View SEC Filing  
11/15/2016Frances K HellerDirectorBuy10,000$3.54$35,400.00View SEC Filing  
8/29/2016Thomas E HughesInsiderBuy10,000$3.00$30,000.00View SEC Filing  
7/26/2016Patricia L. AllenCFOBuy16,000$3.12$49,920.00View SEC Filing  
7/22/2016Frances K HellerDirectorBuy10,000$2.99$29,900.00View SEC Filing  
7/22/2016Thomas E. HughesInsiderBuy5,000$3.02$15,100.00View SEC Filing  
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10View SEC Filing  
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.00View SEC Filing  
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78View SEC Filing  
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Zafgen (NASDAQ:ZFGN)
Latest Headlines for Zafgen (NASDAQ:ZFGN)
DateHeadline logoZafgen Inc (ZFGN) Downgraded by Zacks Investment Research - May 13 at 9:04 AM logoFY2017 EPS Estimates for Zafgen Inc (ZFGN) Raised by Leerink Swann - May 12 at 11:44 AM logoFY2017 Earnings Estimate for Zafgen Inc Issued By SunTrust Banks (ZFGN) - May 12 at 11:44 AM logoInsider Buying: Zafgen Inc (ZFGN) Insider Purchases 10,000 Shares of Stock - May 11 at 8:48 PM logoZafgen Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 11 at 8:26 PM logoZafgen's Second Act - May 11 at 3:25 PM logoZafgen Inc (ZFGN) Issues Earnings Results, Misses Expectations By $0.05 EPS - May 10 at 5:22 PM logoZafgen Inc (ZFGN) Raised to Buy at Zacks Investment Research - May 10 at 11:40 AM logoZafgen Reports First Quarter 2017 Financial Results - May 9 at 8:50 PM logoZafgen reports 1Q loss - May 9 at 8:50 PM logoZafgen updates on obesity drug - Seeking Alpha - May 6 at 3:45 PM logoZafgen Gets One Last Fat Chance - Seeking Alpha - May 6 at 3:45 PM logoZafgen Inc (ZFGN) Scheduled to Post Quarterly Earnings on Monday - May 6 at 1:01 AM logoZafgen Inc (ZFGN) Scheduled to Post Earnings on Monday - May 6 at 12:41 AM logoZafgen (ZFGN) Reports Positive Topline Phase 1 Data for ZGN-1061 - - May 5 at 5:40 AM logoZafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor - May 5 at 5:40 AM logoZafgen Rebounds With a Safer Obesity Drug Targeting Diabetics - May 5 at 5:40 AM logoEdited Transcript of ZFGN earnings conference call or presentation 9-Mar-17 9:30pm GMT - May 3 at 9:32 AM logoEdited Transcript of ZFGN earnings conference call or presentation 10-May-16 8:30pm GMT - May 2 at 6:54 PM logoZafgen Inc (ZFGN) Receives Average Recommendation of "Hold" from Brokerages - May 2 at 2:20 PM logoZafgen (ZFGN) Earns Daily Coverage Optimism Rating of 0.56 - May 1 at 10:44 AM logoZafgen Inc (ZFGN) Expected to Post Earnings of -$0.43 Per Share - April 28 at 1:46 PM logoZafgen (ZFGN) Getting Somewhat Critical Press Coverage, AlphaOne Reports - April 28 at 8:28 AM logoZafgen (ZFGN) Receiving Somewhat Positive Press Coverage, Report Shows - April 25 at 3:12 PM logoZafgen (ZFGN) Earns Daily Media Impact Rating of 0.14 - April 21 at 9:38 AM logoZafgen Inc (ZFGN) Research Coverage Started at Roth Capital - April 20 at 10:58 AM logoSomewhat Negative Media Coverage Somewhat Likely to Effect Zafgen (ZFGN) Share Price - April 13 at 9:20 AM logo Analysts Expect Zafgen Inc (ZFGN) Will Announce Earnings of -$0.45 Per Share - April 7 at 5:35 PM logoZafgen Inc (ZFGN) Receives Consensus Recommendation of "Hold" from Analysts - April 5 at 3:46 PM logoShort Interest in Zafgen Inc (ZFGN) Declines By 8.3% - April 5 at 8:16 AM logoZAFGEN, INC. Financials - March 17 at 5:34 AM logoZafgen Reports Fourth Quarter and Full Year 2016 Financial Results - March 11 at 11:29 AM logo4:11 pm Zafgen beats by $0.12, reports no revenue - March 11 at 11:29 AM logoZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 11 at 11:29 AM logoZAFGEN, INC. Files SEC form 10-K, Annual Report - March 11 at 11:29 AM logoCowen and Company Reiterates Hold Rating for Zafgen Inc (ZFGN) - March 11 at 10:54 AM logoZafgen Inc (ZFGN) Receives Consensus Rating of “Buy” from Analysts - March 10 at 2:45 PM logoZafgen Inc Expected to Earn FY2016 Earnings of ($2.28) Per Share (ZFGN) - March 9 at 10:48 AM logoZafgen Inc (ZFGN) Stock Rating Reaffirmed by FBR & Co - March 9 at 9:00 AM logoZafgen (ZFGN) Presents At Cowen and Company 37th Annual Health Care Conference - March 9 at 6:30 AM logoZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results - March 3 at 8:08 AM logoZafgen to Present at Upcoming Investor Conferences - GlobeNewswire (press release) - March 1 at 8:01 AM logoZafgen to Present at Upcoming Investor Conferences - February 28 at 8:45 PM logoZafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference - February 10 at 6:50 AM logoZafgen Inc. (ZFGN) Has Surged To Over A 5-Month High - January 7 at 6:37 AM logoZafgen upgraded by JMP Securities - January 7 at 6:37 AM


Zafgen (ZFGN) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff